Health ❯ Healthcare

Biotechnology

Drug Development Clinical Trials Gene Therapy Cancer Treatment Pharmaceuticals Gene Editing Therapeutics Immunotherapy Clinical Research Vaccine Development

Jeito Capital Closes $1.2 Billion Jeito II, Setting Record for Independent European Biopharma Funds

The raise signals deeper pools of long-term capital for European drug developers.

CRISPR Therapeutics’ Pipeline Pitched as Path to One-Time Heart Risk Treatments

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Investor Class Actions Target Atara Over FDA Setbacks to EBVALLO

FDA Grants Accelerated Approval to Kresladi, First Gene Therapy for Severe Pediatric LAD-1

ImmunityBio Sued in Securities Class Action Over Anktiva Marketing Claims

DBV Technologies Files 2025 Annual Report, Extends Runway as 2026 Peanut Patch Filings Near

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

FDA Grants Accelerated Approval to Avlayah for Neurologic Manifestations of Hunter Syndrome

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

Sanofi Licenses Kali’s Tri-Specific Autoimmune Antibody KT501 in Deal Worth Up to $1.23 Billion

Plaintiff Firms Intensify Biotech Securities Suits as Key Deadlines Near for Nektar, uniQure and REGENXBIO

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Apogee to Report 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis Today

RTW Buys $116 Million of Cogent Biosciences as Kynam Trims $48 Million Stake

Taysha Advances Rett Gene Therapy Program With Pivotal Dosing, FDA Alignment and Q2 Data Timeline

Arvinas’ ARV-102 Hits >50% LRRK2 Degradation in Phase 1 Parkinson’s Trial

uniQure Investors Face April 13 Deadline in Securities Class Action Over FDA Setback